SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are a good option for glycemic control in patients with T2D,with the added benefit of small reductions in body weight and systolicBP.32 However, the magnitude of A1C lowering is reduced as eGFRdeclines, given the reduced ability of the impaired kidney to excrete glucoseinto urine.